Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab Combined With Cryoablation for Early-Stage NSCLC
NCT07064876Phase 2Not yet recruiting
- Start
- Oct 2025
- Primary completion
- Oct 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of serplulimab in non-small cell lung cancer (NSCLC). Planned start Oct 2025; status: not yet recruiting.
02
Drugs
serplulimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07064876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07064876.